3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Lung Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Rectal Neoplasms
1
Pleural Effusion
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Insulin-Like Growth Factor I, Resistance To
1
Adenocarcinoma
1
Interventions
vandetanib
2
Cisplatin
2
dalotuzumab
1
X-Rays
1
Tissue Plasminogen Activator
1
Receptors, Vascular Endothelial Growth Factor
1
Pemetrexed
1
Octreotide
1
Naproxen
1
Gemcitabine
1
Cdc25C phosphatase (211-221)
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pleural Effusion
×
dalotuzumab
×
Clear all
NCT00799240
2014-11-07
IMPACT
University of Kansas Medical Center
Phase 2
Completed
27 enrolled